Utilization of the nephrectomized mouse for determining threshold effects of MRI contrast agents.
The tissue concentration of an extravascularly distributed MRI contrast agent required to achieve a 20% change in the MRI signal intensity (SI) of skeletal muscle was determined using radiolabeled gadoteridol administered to nephrectomized mice. This minimal change in the quantified SI was reliably detected qualitatively in the MR muscle images. MR images of muscle were acquired following each intravenous injection of six sequential doses of 0.8 micromol of 153Gd-labeled gadoteridol. A 2.0 T imaging spectrometer and a T1-weighted spin-echo pulse sequence were used to acquire the MR images. After imaging, the injected 153Gd in muscle was measured, and the 153Gd assay results were used to determine the gadoteridol concentration in muscle following each injection. The muscle concentrations of gadoteridol were then correlated to the quantified enhanced MR SI of muscle. Using the 20% factor, it was concluded that the amount of gadoteridol necessary to achieve a reliable change in the SI of muscle was 33+/-10 nmol/g-skeletal muscle.
Wedeking
P
P
Chemical and Biological Evaluations, Bracco Research USA, Princeton, NJ 08540, USA.
Shukla
R
R
Kouch
Y T
YT
Nunn
A D
AD
Tweedle
M F
MF
D000818:Animals; D003287:Contrast Media / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D005682:Gadolinium; D006571:Heterocyclic Compounds / Q000008:administration & dosage; D008297:Male; D051379:Mice; D018482:Muscle, Skeletal / Q000033:anatomy & histology*; D009392:Nephrectomy; D009942:Organometallic Compounds / Q000008:administration & dosage; D014018:Tissue Distribution
D003287:Contrast Media; D006571:Heterocyclic Compounds; D009942:Organometallic Compounds; C062402:gadoteridol; D005682:Gadolinium